By Katherine Hamilton

Edwards Lifesciences said it no longer plans to acquire JenaValve after the Federal Trade Commission moved to block the deal.

A Washington, D.C., district court granted a motion from the FTC for an injunction blocking the proposed merger, the heart health company said Friday.

Edwards said it disagreed with the decision, saying the acquisition would have been in the best interest of patients.

The company also revised its full-year 2026 adjusted earnings guidance to a range of $2.90 to $3.05, down from $2.80 to $2.95.

The court's decision comes after the FTC in August filed a lawsuit to block the deal. The FTC said in its complaint that the acquisition would limit competition in the aortic regurgitation device market.

Edwards and JenaValve are the only two companies currently conducting clinical trials on transcatheter aortic valve replacement devices to treat aortic regurgitation in the U.S., according to the FTC.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 09, 2026 19:01 ET (00:01 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.